Page last updated: 2024-08-23

torsemide and sulotroban

torsemide has been researched along with sulotroban in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
David, JL; de Leval, X; Delarge, J; Dogné, JM; Massereel, B; Neven, P; Rolin, S; Wauters, J	1
Delarge, J; Dogné, JM; Masereel, B; Michaux, C; Rolin, S	1

Other Studies

2 other study(ies) available for torsemide and sulotroban

Article	Year
Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins, leukotrienes, and essential fatty acids, 2000, Volume: 62, Issue:5 Topics: Adenosine Diphosphate; Binding, Competitive; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Hemostasis; Humans; Hydrazines; Inhibitory Concentration 50; Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Thromboxane; Sulfonamides; Sulfonylurea Compounds; Time Factors; Torsemide	2000
Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins, leukotrienes, and essential fatty acids, 2001, Volume: 65, Issue:2 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents; Aorta; Arachidonic Acid; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Guinea Pigs; Humans; Hydrazines; Inhibitory Concentration 50; Models, Chemical; Muscle, Smooth; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Receptors, Thromboxane; Sulfonamides; Thromboxane-A Synthase; Torsemide; Trachea; Vasoconstrictor Agents	2001

Article

Year

Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function.

Prostaglandins, leukotrienes, and essential fatty acids, 2000, Volume: 62, Issue:5

Topics: Adenosine Diphosphate; Binding, Competitive; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Hemostasis; Humans; Hydrazines; Inhibitory Concentration 50; Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Thromboxane; Sulfonamides; Sulfonylurea Compounds; Time Factors; Torsemide

2000

Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles.

Prostaglandins, leukotrienes, and essential fatty acids, 2001, Volume: 65, Issue:2

Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents; Aorta; Arachidonic Acid; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Guinea Pigs; Humans; Hydrazines; Inhibitory Concentration 50; Models, Chemical; Muscle, Smooth; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Receptors, Thromboxane; Sulfonamides; Thromboxane-A Synthase; Torsemide; Trachea; Vasoconstrictor Agents

2001